Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis  by Moreira, Andre L. et al.
373Journal of Thoracic Oncology ®  •  Volume 10, Number 2, February 2015
Background: The characterization of the molecular alterations in 
thymic epithelial tumors may lead to a better understanding of tumor-
igenesis, new therapeutic targets, and biomarkers in these tumors.
Methods: Paired tissue (tumor and matched normal) from 15 thy-
mic carcinomas (TCA) and six B3 thymomas were evaluated by exon 
capture of 275 cancer-related genes, followed by deep coverage next-
generation sequencing, which identifies somatic sequence variants, 
small insertions and deletions, and copy number alterations involv-
ing all exons of the captured genes.
Results: Non-silent somatic mutations were identified in 12 of 15 
(80%) TCA with a median of one mutation per tumor (range 0–26). 
Recurrent mutations were identified in tumor suppressor genes TP53 
(n = 4), SMAD4 (n = 2), and CYLD (n = 2); and chromatin remodel-
ing genes KDM6A (n = 3), SETD2 (n = 2), MLL3 (n = 2), and MLL2 
(n = 2). Tumors with TP53 mutation appeared to exhibit more aggres-
sive behavior. Therefore, the role of P53 was evaluated by immunohis-
tochemistry in an additional ten cases. P53 overexpression correlated 
with TP53 mutation. These tumors had a higher rate of recurrence and 
death of disease compared to carcinoma with normal p53 expression 
(p = 0.02 for disease-free survival and p = 0.05 for overall survival). 
Among the B3 thymomas, mutations were identified in four of six 
tumors. Mutations in BCOR (BCL6 co-repressor) were seen in three 
thymomas and MLL3 (involved in histone methylation) in one tumor.
Conclusions: Next-generation sequencing of cancer genes in thymic 
epithelial tumors revealed a low frequency of mutation, with differ-
ent patterns between TCA and B3 thymomas. TP53 and BCOR were 
the most frequently mutated genes in TCA and B3 thymomas, respec-
tively. Alterations in p53 are associated with worse prognosis in TCA.
Key Words: Next-generation sequencing, Thymoma, Thymic 
carcinoma.
(J Thorac Oncol. 2015;10: 373–380)
Thymoma is a rare tumor of thymic epithelial cells with an estimated incidence of 0.13 per 100,000 persons a year.1 
Thymomas represent a group of tumors with heterogeneous 
histological patterns,2 but a relatively homogeneous clinical 
history. In general, patients with thymoma have an indolent 
course of disease with a tendency for multiple local recur-
rences with later systemic metastases. Thymic carcinomas 
(TCA) are rarer than thymomas and have a more aggressive 
behavior. TCA are characterized histologically by overtly 
cytological malignant tumor cells. TCA are also heterogeneous 
histologically with squamous cell carcinoma as the most com-
mon histological presentation.
Outcomes for patients with thymic tumors depend 
largely upon stage and histologic type. For thymomas, WHO 
Type A and B1 thymomas are considered to be low-grade 
tumors, whereas WHO Type B3 thymoma has a more aggres-
sive behavior.3–5 However, measurements of outcome have 
not been standardized and are particularly problematic in 
thymic neoplasms due to the rarity of these tumors and pace 
of disease progression.6 Ten-year disease-specific survival is 
approximately 20% for stage 4 thymomas.6 TCA are typi-
cally invasive and more aggressive with a high risk of recur-
rence, distant metastasis, and short survival.6,7 Surgery is the 
mainstay of treatment for thymoma and TCA, whereas che-
motherapy is offered to patients with more advanced disease 
either pre-operatively with intent for optimization of surgical 
resection or as palliative therapy for patients with unresect-
able disease.8 Despite reproducible response rates, complete 
response (radiographic or pathologic) to chemotherapy is rare. 
Therefore, new therapeutic strategies for the management of 
thymoma and TCA are needed. There have been very few 
studies dedicated to the understanding of the biology of thy-
momas and TCA, partially due to the rarity of these tumors. 
An improved appreciation of the molecular characteristics of 
thymic epithelial tumors may lead to identification of mol-
ecules that can be targeted therapeutically, thus opening new 
treatment options for the patients who suffer from these dis-
eases. In addition, these studies may also identify biomarkers 
that can be potentially used for the clinical management of 
these patients.
Earlier studies have demonstrated that TCA are molecu-
larly different from thymomas. Molecular differences between 
thymomas type A from type B are also seen. Thymomas type 
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A show low frequency of allelic imbalances when compared 
to types B2–B3.9–12
The most comprehensive molecular analyses of thymic 
tumors have focused on the epidermal growth factor receptor 
(EgFR) and tyrosine protein kinase kit pathway, which can be 
targeted therapeutically with specific drugs. EGFR mutations 
have been reported in thymomas with a low frequency and a 
case report demonstrating response to gefitinib stimulated 
interest in this pathway. However, in other series, no somatic 
mutations in the EGFR gene were identified.9,12–17 Moreover, 
a previous study from our center involving profiling at muta-
tional hotspots in seven genes mediating EgFR signaling 
(KRAS, HRAS, BRAF, PIK3CA, ERBB2, MEK1, and EGFR) 
identified somatic mutations in just 7% of tumors (two KRAS 
and one HRAS mutation) suggesting that analysis of additional 
pathways are required to identify driver oncogenes in thymic 
tumors.9 Expression of KIT can be identified by immunohisto-
chemistry in approximately 60% of TCA but not in thymomas, 
suggesting that activation of this pathway is important for TCA 
pathogenesis.13,16,18,19 An objective response to a KIT inhibitor 
(imatinib) in a patient with TCA harboring an activating KIT 
mutation has been described in a case report.20 However, in 
broader analyses, KIT mutations appear to be relatively uncom-
mon in TCA and absent in thymomas.9,14,15,17,21 Therefore, a 
better understanding of the biology and the molecular mecha-
nisms in these tumors is essential for the formulation of new 
rationales for therapeutic intervention.22
Recent advances in DNA sequencing have enabled 
large-scale genomic characterization of tumor samples at 
increased throughput and sensitivity and decreased cost com-
pared to more traditional methods. Through exon capture by 
hybridization, one can isolate and sequence dozens of genes 
up to the entire exome. We applied this technology to analyze 
275 key cancer-associated genes, encompassing all known tar-
getable “driver” alterations. This approach can identify muta-
tions, gene amplifications, and other molecular alterations in 
all target cancer genes simultaneously with a small amount 
of input DNA, and it has been validated for use with DNA 
obtained from frozen and paraffin-embedded tissue.23,24
MATERIALS AND METHODS
Tumors
The study had the approval from the MSKCC 
Institutional Review Board Committee. Fifteen TCA and six 
thymomas WHO type B3 that had been resected in the hos-
pital between 2004 and 2010 were identified retrospectively 
from a database prospectively maintained by the Thoracic 
Service of the Department of Surgery of Memorial Hospital. 
Fourteen TCA were classified as squamous cell carcinoma and 
one tumor was classified as an undifferentiated TCA. Patients 
were staged according to the Masaoka-Koga staging criteria.25
DNA Extraction
Fresh frozen tissue or paraffin-embedded tissue from 
tumor and normal paired tissue were evaluated, confirmed, 
and marked by a pathologist (ALM), and samples underwent 
microdissection followed by DNA extraction. DNA extraction 
for all samples was performed using the Qiagen DNeasy 
Blood and Tissue Kit standard protocol. Sample concentration 
and purity were confirmed with a Qubit Fluorometer.
Sequencing
genomic alterations in key cancer-associated genes 
were profiled using a custom capture, deep sequencing assay 
termed integrated mutation profiling of actionable cancer tar-
gets (IMPACT). Hybridization capture of Illumina-compatible 
sequence libraries (Kapa Biosystems, Wilmington, MA) was 
performed using custom oligonucleotides (Nimblegen SeqCap, 
Madison, WI) designed to target all protein-coding exons and 
selected introns of 275 commonly implicated oncogenes, 
tumor suppressor genes, and members of pathways consid-
ered actionable by targeted therapies. DNA was subsequently 
sequenced on an Illumina HiSeq 2000 as paired-end 75-base 
pair reads to an average read depth of 435-fold per tumor (277-
fold per normal). Sequence reads were aligned to the reference 
human genome (hg19) using the Burrows–Wheeler Alignment 
tool26 and post-processed using the genome Analysis Toolkit 
(gATK).27 Single nucleotide variants, small insertions 
and deletions, and copy number alterations were called as 
described elsewhere.24 A list of the 275 genes included in the 
assay is presented in Supplementary Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A740). Two out 
of 15 TCA samples were captured using a smaller probe set 
comprised of only 230 of the 275 genes. A TP53 mutation was 
found in one tumor using the 230 gene panel.
Immunohistochemical stain. To evaluate a possible cor-
relation between p53 mutation and aggressive behavior, an 
additional 10 cases of TCA were evaluated for p53 expression 
by immunohistochemical stain. Histological sections of TCA 
and B3 thymomas were evaluated for p53 expression (mono-
clonal antibody clone DO-7, Ventana, USA) in an automated 
stainer (BenchMark XT, Ventana, USA). Although there is no 
perfect correlation between p53 expression by immunohisto-
chemistry (IHC) and mutation, we used the criteria set forth 
by Yemelyanova et al.28 Tumor that showed diffuse overexpres-
sion of p53 defined by strong expression in more than 60% of 
tumor cells or lack of staining with the anti-p53 antibody are 
considered to be consistent with p53 mutation. Tumors with 
scattered positive cells or low level expression (less than 50%) 
are considered to be negative for mutation.
Statistical Analysis
We used descriptive measures (χ2 test) to compare the 
association between quantity and quality of mutations within 
groups. Disease-free survival (DFS) was defined as the time 
from resection to recurrence or lung cancer-related death. 
Cause of death was determined from the death certificate or 
physician correspondence. Last follow-up, death from other 
causes, and unknown cause of death were censored. Overall 
survival (OS) is defined as time of death after surgery. DFS 
and OS were estimated using the Kaplan–Meier method. 
Associations between p53 expression, DFS, and OS were 
evaluated using Cox proportional hazards models. All statisti-
cal analyses were performed using graphPad Prism 5 soft-
ware (graphPad Software, La Jolla, CA).
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RESULTS
Study Population
The clinicopathological characteristics of the patients 
enrolled in the study are illustrated in Table 1. There were a 
similar distribution of man and woman among the groups of 
TCA and thymoma. Patients with thymoma were younger than 
patients with TCA. All patients with thymoma type B3 pre-
sented with advanced stage and received neoadjuvant therapy 
before surgery in contrast to eight patients in the TCA group 
that received neoadjuvant therapy.
Detection of Mutation in 
Thymic Epithelial Tumors
All samples passed quality assurance tests, with mean 
sequence coverage of 435× per tumor. Two TCA had both fro-
zen tissue and corresponding paraffin-embedded tissue avail-
able for analysis, and no discrepancies were detected, similar 
to what has been previously reported.23
Fourteen TCA were classified as squamous cell carci-
noma and one classified as undifferentiated carcinoma (Table 2). 
Somatic non-synonymous protein-coding mutations were iden-
tified in 12 of 15 (80%) TCA. The rate of mutation per tumor 
was low with a median of one mutation per tumor (range 0–26) 
(Fig. 1). The most frequent mutations were seen in the tumor 
suppressor genes TP53 (n = 4), SMAD4 (n = 2), and CYLD (n 
= 2); and chromatin remodeling genes KDM6A (n = 3), SETD2 
(n = 2), MLL3 (n = 2), and MLL2 (n = 2) (Fig. 2). In this small 
sample, it appears that there were no significantly co-occurring 
or mutually exclusive mutations in TCA. There were no muta-
tions identified in KIT, and one tumor had a Q61K mutation 
in neuroblastoma RAS viral (v-ras)oncogene (NRAS). Table 2 
shows the complete list of mutations identified in this cohort.
The undifferentiated TCA had 26 identifiable mutations. 
This tumor came from a patient who presented with stage 4b, 
and received neoadjuvant therapy before surgery. A thymic 
origin was confirmed by immunohistochemistry expression of 
CD5 and KIT in tumor cells. This tumor also had two sepa-
rate mutations in KDM6A and MLL2 (Table 2). Overall there 
was no significant difference in the number of mutations in 
the group that received neoadjuvant therapy and the untreated 
group (p = 0.59).
Among the B3 thymomas, mutations were identified in 
four of six tumors. Mutations in BCOR (BCL6 co-repressor) 
were seen in three thymomas and MLL3 (involved in histone 
methylation) was seen in one tumor. It is interesting to note that 
there were three TCA and two B3 thymomas that harbored no 
mutations in the 275 genes studied, though it is possible that 
mutations were present and not detected due to sub clonality. 
All specimens were adequate for tumor cellularity. Among the 
three TCA with no detectable mutations, two patients were in 
the treated group and one in the untreated group.
TCA showed areas of chromosomal instability charac-
terized by gains and losses. The most frequent gains involved 
chromosomes 1q and 5p, and the most frequent losses 
involved chromosomes 3p and 6. No chromosomal gains and 
losses were detected in B3 thymomas.
Immunohistochemical Stains for p53
In this small sample, three out of four TCA with TP53 
mutation appeared to exhibit more aggressive behavior. Three 
patients presented as Masaoka stage 4 (two patients had 4b and 
one 4a) and received neoadjuvant therapy. Two patients with 
TP53-mutated TCA died of disease (mean survival 2.2 years), 
and the third is alive with disease. In contrast, in the group of 
patients without TP53 mutations, there were four patients with 
stage 4a at presentation, two are alive with disease, and two 
died of unrelated causes (mean follow-up 8 years). All other 
TCA patients were Masaoka stage 1 to 3 at diagnosis and are 
alive since last follow-up.
To evaluate a possible correlation between p53 mutation 
and aggressive behavior, an additional 10 cases of TCA were 
evaluated for p53 expression by immunohistochemical stain. 
Mutations in the TP53 have previously been shown to correlate 
strongly with upregulated p53 expression as measured by IHC.28
There was perfect correlation between TP53 muta-
tion and p53 expression by IHC. All cases that had mutation 
showed over expression of p53 in more than 60% of tumor 
nuclei. All cases of TCA that were negative for TP53 mutation 
by next-generation sequencing had only focal positive stain-
ing in tumor nuclei (Fig. 3).
From the additional 10 cases of TCA, the staining pat-
tern in three tumors were considered to be consistent with p53 
mutation; one tumor showed over expression of p53 and two 
showed complete absence of stain. Seven cases had focal posi-
tivity in tumor nuclei and therefore scored as negative.
None of the six B3 thymomas evaluated showed alter-
ation in the p53 by IHC, similar to what we observed from 
sequencing. All B3 thymomas showed focal reactivity for p53 
in less than 10% of tumor nuclei.
Association of p53 Expression 
and Disease Progression
To evaluate an association of TP53 mutation and disease 
progression, the expression pattern of p53 mutation by IHC was 
TABLE 1.  Clinicopathological Characteristics of Study 
Population 
Thymoma B3 Thymic Carcinoma
Sex
Male 2 5
Female 4 10
Age
Mean ± SD 45 ± 8 61 ± 11
Range 34–59 43–79
Tumor size
Mean ± SD 6.3 ± 2.5 cm 6 ± 2.2 cm
Range 3.6–10 cm 2–9 cm
Masaoka stage
1 0 2
2 0 3
3 0 3
4 6 7
Neoadjuvant  6 8
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correlated with DFS and OS. As illustrated in Figure 4, survival 
analysis showed that TCA with staining patterns consistent with 
p53 mutation had a 5-year DFS of 12.5% compared with 54% 
in the group with wild-type p53 staining pattern (p = 0.02, HR: 
0.2848, 95% CI of ratio 0.06 to 0.72). The median survival for 
patients with mutated p53 was 2 years (731 days), whereas 
median survival could not be defined for the p53 wild type group. 
Interestingly, there was also a trend of poor prognosis in OS for 
patients with TCA that overexpressed p53 by IHC (p = 0.05).
DISCUSSION
This study represents, to the best of our knowledge, the 
most comprehensive mutation profiling analysis of TCA con-
ducted to date. Our results are consistent with prior reports9,29 
confirming a low rate of mutation in these tumors. This low 
rate of mutations is not related to inadequate sensitivity of the 
technique used, because we obtained deep sequence coverage 
with an average of 435× for the evaluated exons. It is pos-
sible that the analysis of larger numbers of tumors may reveal 
other significantly mutated genes. Furthermore, whole exome 
sequencing may reveal additional clinically or biologically 
relevant mutations in other genes outside of the 275 cancer-
related genes that were captured by our assay.
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FIGURE 1.  Illustration of the number of somatic non-synon-
ymous protein-coding mutations per thymic carcinoma. Each 
bar represents one tumor. Red bar The number of mutations 
seen in a random pulmonary adenocarcinoma. Note that in 
three thymic carcinomas, no mutations were identified in the 
panel of 275 cancer-related genes.
FIGURE 2.  Illustration of the number of the most frequent 
mutations identified in thymic carcinoma.
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Despite several publications in the field of TCA suggest-
ing that KIT mutations are present in these tumors, we did not 
detect mutations in the gene in any of the 15 TCA evaluated. 
Previous studies have showed a low rate of KIT mutations in 
TCA,9,21,30–32 thus our sampling of only 15 cases may be in part 
responsible for our negative KIT results.
Several studies have suggested that TCA and B3 thymo-
mas have different molecular signatures.9,33,34 Our data further 
support these findings. In our series, none of the B3 thymomas 
evaluated had mutations in p53 gene or showed chromosomal 
gains or losses, which were commonly observed in TCA. In 
contrast, none of the TCA had mutation in BCOR, which we 
observed repeatedly in B3 thymomas.
It is interesting to note that a recent study presenting a 
molecular analysis of one B3 thymoma also reported a muta-
tion in BCOR.35 It is possible that BCOR (BCL6-corepressor) 
may be a marker of B3 thymoma. Further studies evaluating 
the role of this mutation in other thymoma subtypes are needed 
to confirm these observations. BCOR, a gene related to germi-
nal center formation and prevention of apoptosis, is frequently 
mutated in acute myeloid leukemia (AML) and other myelo-
dysplastic syndromes.36 In hematological diseases, mutations 
in BCOR are associated with poor prognosis. The role of this 
gene in thymomas is currently unclear.
Mutations in TCA were frequently observed in tumor 
suppressor genes and chromatin remodeling genes. p53 is 
a tumor suppressor gene and the most commonly mutated 
gene in human malignant tumors.37 TCA is not an exception. 
Although data in TCA are sparse, it has been shown in smaller 
series by polymerase chain reaction and other techniques that 
mutations in the p53 gene can be seen in approximately 30% 
of TCA,38,39 similar to our study. Although there is no targeted 
therapy toward p53-mutated tumors, the mutation status and/
or overexpression of p53 may be used as prognostic marker 
in TCA. p53 mutant TCA seem to be associated with a more 
aggressive behavior, confirming earlier reports.38–40 Similar 
observations have also been made in other tumors with p53 
mutation.41,42 As no mutations in p53 were observed in six 
cases of B3 thymoma, it is possible that mutation in this gene 
is a marker of TCA compared with thymomas.
Other tumor suppressor genes mutated in TCA are 
SMAD4 and CYLD. The former is a gene involved in the trans-
forming growth factor beta (TgF-β) pathway. Mutations in 
SMAD4 often lead to loss of expression and are associated with 
worse prognosis in colon and pancreatic cancers.44,45 CYLD is 
involved in another inflammatory pathway, the NF-ĸB pathway. 
germline mutations in the gene are tumorigenic to epithelial 
cells, and are associated with familial cylindromatosis that leads 
to multiple benign skin adnexal tumors.46 Somatic mutations 
in CYLD are rare in solid tumors47 and have been described 
in TCA.48 Notably, both mutations we observed in CYLD are 
truncating mutations: one is a nonsense mutation (p.S371*) and 
the other is a frameshift deletion (p.I92fs). The possible role for 
these genes in the biology of TCA remains to be evaluated.
FIGURE 3.  Expression of p53 by immunohistochemistry. A, The staining pattern of a thymic carcinoma with wild-type TP53. 
Note scattered positive nuclei representing less than 10% of the tumor cells. B, The staining pattern of p53 in a thymic car-
cinoma with TP53 mutation. Note positive nuclei in more than 60% of tumor cells. There was a perfect correlation between 
mutation and immunohistochemistry staining pattern in these cases.
FIGURE 4.  Relationship of p53 expression by immunohisto-
chemistry and disease-free survival Kaplan–Meier curve in 25 
cases of thymic carcinoma (p = 0.0205). Similar observation 
was seen when overall survival was analyzed (p = 0.0545) 
(not shown).
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Chromatin remodeling genes are associated with epi-
genetic regulation, and mutations in this class of genes are 
commonly seen in solid tumors.49–52 Mutations in several 
chromatin remodeling genes were observed in our series, with 
multiple mutations in KDM6A, SETD2, MLL2, and MLL3 in 
TCA. All identifiable mutations in B3 thymomas were in this 
class, with recurrent mutations in BCOR and a single muta-
tion in MLL3. There has been a renewed interest in the study 
of chromatin remodeling genes in carcinogenesis due to the 
potential of targeting these genes for therapy.53
All B3 thymomas and eight out of 15 TCA received 
neoadjuvant therapy before resection, a standard practice for 
thymic epithelial tumors that present with advanced clinical 
stage. Although chemotherapy and or radiation can induce 
somatic mutations,54 there was no difference in the number 
of observed mutations between treated and untreated TCA (p 
> 0.005). It is possible that chemotherapy-induced mutations 
were present but not detected due to subclonality in the evalu-
ated tumors and the time required for their development.
In summary, TCA show a relatively low rate of muta-
tions compared with other solid tumors. Similar to most car-
cinomas, mutations in p53 are most frequent and seem to be 
associated with more aggressive behavior. Further studies 
involving more cases and the sequencing of an expanded 
panel of genes are warranted for a better understanding of the 
oncogenic mechanisms in these rare tumors.
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